[go: up one dir, main page]

Adamicovat et al., 1995 - Google Patents

XVth European Congress of Pathology

Adamicovat et al., 1995

Document ID
15557232846198120779
Author
Adamicovat D
Beseda A
Polacek H
Pecs J
Publication year
Publication venue
Path. Res. Pract

External Links

Continue reading at scholar.google.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate

Similar Documents

Publication Publication Date Title
Tran et al. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas
Kinsella et al. The role of the cell-cell adhesion molecule E-cadherin in large bowel tumour cell invasion and metastasis
Wright Management of thymomas
Epstein et al. Immunohistochemical localization of prostate-specific acid phosphatase and prostate-specific antigen in stage A2 adenocarcinoma of the prostate: prognostic implications
Janossy et al. Immuno-histological diagnosis of lymphoproliferative diseases by selected combinations of antisera and monoclonal antibodies
CN101389658A (en) Cytotoxicity mediation of cells evidencing surface expression of cd59
Nesiu et al. Intracellular chloride ion channel protein-1 expression in clear cell renal cell carcinoma
Walentowicz‐Sadlecka et al. The analysis of human leukocyte antigen‐G level in patients with endometrial cancer by Western blot technique
Sa-Ngiamwibool et al. Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features
AU5990096A (en) A highly sensitive immunocytochemical method for diagnosis of malignant effusions
Kordek et al. Apoptosis in glial tumors as determined by in situ nonradioactive labeling of DNA breaks
Kinoshita et al. Genomic‐based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma
Adamicovat et al. XVth European Congress of Pathology
Bostwick et al. Prostatic intraepithelial neoplasia and well differentiated adenocarcinoma maintain an intact basement membrane
US7364868B2 (en) Krüppel-like transcriptional factor KLF4/GKLF and uses thereof
Yashiro et al. CD54 expression is predictive for lymphatic spread in human gastric carcinoma
US8999657B2 (en) Reagents, methods, and kits for the classification of cancer
JP4868152B2 (en) Cancer cell malignancy assessment method
US20100081192A1 (en) Early prostate cancer antigens (epca), polynucleotide sequences encoding them, and their use
EP0935757A1 (en) Assessment of cervical cells
Righi et al. Prognostic role of bone sialoprotein in clear cell renal carcinoma
Erbersdobler et al. Numerical chromosomal anomalies in latent adenocarcinomas of the prostate
Mai et al. Absence of serum prostate-specific antigen and loss of tissue immunoreactive prostatic markers in advanced prostatic adenocarcinoma after hormonal therapy: a report of two cases
Rosen et al. Determination of placental ferritin-positive peripheral lymphocytes in early stages of breast cancer
JPH0678787A (en) Monoclonal antibody against human mucinous ovarian tumor and detection of human ovarian tumor with the antibody